

Miriam K Elfström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2640948/publications.pdf>

Version: 2024-02-01

61
papers

3,299
citations

361296

20
h-index

155592

55
g-index

62
all docs

62
docs citations

62
times ranked

3385
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Feasibility of sending a direct send HPV self-sampling kit to long-term non-attenders in an organized cervical screening program. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 268, 68-73. | 0.5 | 2 |
| 2 | Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1522-1528. | 0.8 | 20 |
| 3 | Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. <i>Preventive Medicine</i> , 2021, 144, 106293. | 1.6 | 10 |
| 4 | Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. <i>Clinical Infectious Diseases</i> , 2021, 72, e890-e892. | 2.9 | 5 |
| 5 | The cost-effectiveness of prostate cancer screening using the Stockholm3 test. <i>PLoS ONE</i> , 2021, 16, e0246674. | 1.1 | 11 |
| 6 | High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers. <i>Journal of Infectious Diseases</i> , 2021, 224, 14-20. | 1.9 | 8 |
| 7 | Elimination of HPV-associated oropharyngeal cancers in Nordic countries. <i>Preventive Medicine</i> , 2021, 144, 106445. | 1.6 | 9 |
| 8 | Antibodies to SARS-CoV-2 and risk of past or future sick leave. <i>Scientific Reports</i> , 2021, 11, 5160. | 1.6 | 8 |
| 9 | SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden. <i>Journal of Internal Medicine</i> , 2021, 290, 430-436. | 2.7 | 4 |
| 10 | Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. <i>Scandinavian Journal of Public Health</i> , 2021, 49, 707-712. | 1.2 | 10 |
| 11 | Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial. <i>PLoS Medicine</i> , 2021, 18, e1003748. | 3.9 | 9 |
| 12 | Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>Value in Health</i> , 2021, 24, 1763-1772. | 0.1 | 7 |
| 13 | Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic. <i>PLoS ONE</i> , 2021, 16, e0257854. | 1.1 | 5 |
| 14 | Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters. <i>Preventive Medicine Reports</i> , 2021, 23, 101399. | 0.8 | 11 |
| 15 | Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827. | 1.6 | 9 |
| 16 | Exposure Definition in Case-Control Studies of Cervical Cancer Screening: A Systematic Literature Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2154-2166. | 1.1 | 3 |
| 17 | Early assessment of the first wave of the COVID-19 pandemic on cancer screening services: The International Cancer Screening Network COVID-19 survey. <i>Preventive Medicine</i> , 2021, 151, 106642. | 1.6 | 39 |
| 18 | Differences in risk for SARS-CoV-2 infection among healthcare workers. <i>Preventive Medicine Reports</i> , 2021, 24, 101518. | 0.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers. PLoS ONE, 2021, 16, e0260453. | 1.1 | 3 |
| 20 | Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination. American Journal of Obstetrics and Gynecology, 2021, , . | 0.7 | 0 |
| 21 | Cervical cancer caseâ€“control audit: Results from routine evaluation of a nationwide cervical screening program. International Journal of Cancer, 2020, 146, 1230-1240. | 2.3 | 32 |
| 22 | Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. American Journal of Obstetrics and Gynecology, 2020, 222, 253.e1-253.e8. | 0.7 | 19 |
| 23 | Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative crossâ€“sectional surveys of more than 100,000 women. Acta Obstetrica Et Gynecologica Scandinavica, 2020, 99, 175-185. | 1.3 | 31 |
| 24 | Baseline findings and safety of infrequent <i>vs</i>. frequent screening of human papillomavirus vaccinated women. International Journal of Cancer, 2020, 147, 440-447. | 2.3 | 8 |
| 25 | HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine, 2020, 383, 1340-1348. | 13.9 | 723 |
| 26 | Commentary: Back to the future in cervical screening: applying a contemporary lens to an old controversy. Journal of Clinical Epidemiology, 2020, 127, 218-219. | 2.4 | 2 |
| 27 | Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes. Acta Oncologica, 2020, 59, 1308-1315. | 0.8 | 5 |
| 28 | Impact of HPV vaccination on cervical screening performance: a population-based cohort study. British Journal of Cancer, 2020, 123, 155-160. | 2.9 | 40 |
| 29 | Emergency contraceptive pill use among women in Denmark, Norway and Sweden: Populationâ€“based survey. Acta Obstetrica Et Gynecologica Scandinavica, 2020, 99, 1214-1221. | 1.3 | 6 |
| 30 | Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. International Journal of Cancer, 2020, 147, 1855-1863. | 2.3 | 6 |
| 31 | Importance of International Networking and Comparative Research in Screening to Meet the Global Challenge of Cancer Control. JCO Global Oncology, 2020, 6, 180-181. | 0.8 | 4 |
| 32 | Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. International Journal of Cancer, 2020, 147, 9-13. | 2.3 | 6 |
| 33 | Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. PLoS Medicine, 2020, 17, e1003035. | 3.9 | 36 |
| 34 | Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study. BMJ Open, 2020, 10, e039636. | 0.8 | 7 |
| 35 | HPVâ€“mRNA and HPVâ€“DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. International Journal of Cancer, 2019, 144, 1073-1081. | 2.3 | 22 |
| 36 | Increasing participation in cervical screening by targeting longâ€“term nonattenders: Randomized health services study. International Journal of Cancer, 2019, 145, 3033-3039. | 2.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1207. | 2.4 | 18 |
| 38 | Contraceptive use at first intercourse is associated with subsequent sexual behaviors. <i>Contraception</i> , 2019, 99, 217-221. | 0.8 | 6 |
| 39 | Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 1377-1381. | 2.9 | 43 |
| 40 | Initial participation as a predictor for continuous participation in population-based colorectal cancer screening. <i>Journal of Medical Screening</i> , 2018, 25, 126-133. | 1.1 | 13 |
| 41 | Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. <i>International Journal of Cancer</i> , 2018, 142, 44-56. | 2.3 | 169 |
| 42 | Cervical cancer screening in Sweden 2014-2016. <i>PLoS ONE</i> , 2018, 13, e0209003. | 1.1 | 17 |
| 43 | High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002666. | 3.9 | 55 |
| 44 | Determinants of the presence of human papillomaviruses in the anal canal of Russian men. <i>Journal of Medical Virology</i> , 2018, 90, 1643-1650. | 2.5 | 6 |
| 45 | Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. <i>BMJ Open</i> , 2017, 7, e014788. | 0.8 | 23 |
| 46 | Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. <i>Journal of Clinical Virology</i> , 2017, 90, 64-69. | 1.6 | 3 |
| 47 | Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 264.e1-264.e7. | 0.7 | 37 |
| 48 | Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: A nationwide cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 48.e1-48.e15. | 0.7 | 19 |
| 49 | Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. <i>PLoS Medicine</i> , 2017, 14, e1002414. | 3.9 | 37 |
| 50 | Registry-based assessment of the status of cervical screening in Sweden. <i>Journal of Medical Screening</i> , 2016, 23, 217-226. | 1.1 | 24 |
| 51 | Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. <i>BMJ, The</i> , 2016, 352, i276. | 3.0 | 40 |
| 52 | Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial. <i>International Journal of Cancer</i> , 2015, 136, 350-359. | 2.3 | 13 |
| 53 | Barriers to and Facilitators of Compliance with Clinic-Based Cervical Cancer Screening: Population-Based Cohort Study of Women Aged 23-60 Years. <i>PLoS ONE</i> , 2015, 10, e0128270. | 1.1 | 25 |
| 54 | Organization and quality of HPV vaccination programs in Europe. <i>Vaccine</i> , 2015, 33, 1673-1681. | 1.7 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Cervical cancer screening in Europe: Quality assurance and organisation of programmes. <i>European Journal of Cancer</i> , 2015, 51, 950-968. | 1.3 | 127 |
| 56 | Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. <i>PLoS ONE</i> , 2015, 10, e0127444. | 1.1 | 7 |
| 57 | Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination. <i>Current Opinion in Oncology</i> , 2014, 26, 120-129. | 1.1 | 13 |
| 58 | Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532. | 6.3 | 1,282 |
| 59 | Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. <i>BMJ, The</i> , 2014, 348, g130-g130. | 3.0 | 103 |
| 60 | Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171. | 1.1 | 21 |
| 61 | A pilot study of risk-stratified cervical cancer screening. <i>Open Research Europe</i> , 0, 1, 84. | 2.0 | 0 |